{"id":"de-117-ophthalmic-solution-qd","_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Prostaglandin E2 receptor EP2","explanation":"DE-117 selectively activates the EP2 prostaglandin receptor subtype, which promotes aqueous humor drainage through the uveoscleral pathway. This mechanism differs from traditional prostaglandin analogs that primarily target the FP receptor, potentially offering an alternative treatment approach for glaucoma patients.","oneSentence":"DE-117 is a selective EP2 receptor agonist that lowers intraocular pressure through increased uveoscleral outflow."},"_scrapedAt":"2026-03-28T03:31:34.530Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123825,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"latanoprost","brand":"Xalatan","company":"Pfizer","rationale":"Prostaglandin analog for glaucoma, once-daily dosing"},{"name":"travoprost","brand":"Travatan","company":"Alcon","rationale":"Prostaglandin analog targeting intraocular pressure reduction"},{"name":"tafluprost","brand":"Zioptan","company":"Santen","rationale":"Preservative-free prostaglandin analog from same company"},{"name":"omidenepag isopropyl","brand":"Omlonti","company":"Santen","rationale":"Selective EP2 agonist for glaucoma from same company"}],"description":"DE-117 ophthalmic solution is an investigational eye drop developed by Santen Inc. for once-daily administration. The drug is currently in Phase 2 clinical development for the treatment of glaucoma and ocular hypertension, conditions characterized by elevated intraocular pressure that can lead to vision loss.","indications":{"approved":[{"status":"investigational","condition":"Glaucoma","patientPopulation":"Adult patients requiring intraocular pressure reduction"},{"status":"investigational","condition":"Ocular hypertension","patientPopulation":"Adult patients with elevated intraocular pressure"}]},"trialDetails":[{"nctId":"NCT03858894","phase":"PHASE2","title":"Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2019-01-28","conditions":"Primary Open-angle Glaucoma and Ocular Hypertension","enrollment":98},{"nctId":"NCT01654484","phase":"PHASE1, PHASE2","title":"A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2012-07","conditions":"Glaucoma and Ocular Hypertension","enrollment":60},{"nctId":"NCT02179008","phase":"PHASE2","title":"Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2014-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DE-117 Ophthalmic Solution QD","genericName":"DE-117 Ophthalmic Solution QD","companyName":"Santen Inc.","companyId":"santen-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}